Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BioNTech, OncoC4 Report Positive Overall Survival Data From Phase 3 Trial of Gotistobart in Lung Cancer

BioNTech, OncoC4 Report Positive Overall Survival Data From Phase 3 Trial of Gotistobart in Lung Cancer

MT newswireMT newswire2026/09/14 09:04
05:04 AM EDT, 09/14/2026 (MT Newswires) -- BioNTech (BNTX) and OncoC4 said Monday that updated data from the first stage of their phase 3 PRESERVE-003 trial showed a statistically significant overall survival benefit for gotistobart in patients previously treated with squamous non-small cell lung cancer. The company said data showed that gotistobart nearly doubled overall survival compared with standard-of-care chemotherapy in 87 patients in the trial. Median overall survival was 18.5 months for patients treated with gotistobart compared with 10 months for those receiving standard-of-care docetaxel chemotherapy, according to the statement. Gotistobart's safety profile "remained manageable" and consistent with previously reported data, the partners added. The companies said about 44 out of every 100 patients taking gotistobart experienced a serious side effect related to the treatment, compared with about 49 out of every 100 patients taking docetaxel. BioNTech shares were up 2.9% in Monday premarket activity.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Google partners with Unity (U.US) to develop a next-generation gaming platform: Create games by simply speaking, no coding required

Google has formed a strategic partnership with Unity, planning to launch an integrated gaming platform within the year that allows for creation with natural language. Unity shares rose nearly 6% in pre-market trading, while Roblox dropped nearly 5%.

智通财经•2026/10/07 13:41

BUZZ - Halozyme shares rise after winning a case against Merck's injectable Keytruda in a Dutch court

October 7 – Halozyme (HALO.O) shares rose 1.4% pre-market to $111.24. Halozyme announced it had obtained an injunction from a Dutch court (link), prohibiting Merck MRK.N from manufacturing, selling, and importing subcutaneous Keytruda in eight European markets. The court determined that Merck had infringed Halozyme’s EP622 patent and rejected Merck’s claims that the patent was invalid. Halozyme stated that patients will still have access to the intravenous version of Keytruda, which is not affected by the injunction. As of the close of the previous trading day, HALO shares have risen 62% this year. (For non-English speakers, Reuters automatically translates its reports into several languages. Due to possible errors or missing context in automated translations, Reuters does not guarantee the accuracy of such translated texts, which are provided for readers’ convenience only. Reuters assumes no liability for any damages or losses caused by use of the automated translation function.)

路透社•2026/10/07 13:31

BUZZ-KeyBanc upgrades Corteva rating to "Overweight"; stock price rises

On October 7, KeyBanc upgraded the rating of agricultural technology company Corteva Inc (CTVA.N) from "Sector Weight" to "Overweight." CTVA rose 1.6% in pre-market trading to $14.1. The brokerage pointed out that new product launches, cost reductions, and improvements in farmers' economic conditions will be strong growth drivers for 2028-2029. The company’s ample cash reserves enable it to flexibly fund growth initiatives, stock buybacks, and potential acquisitions. Out of 23 brokerages, 16 have given the stock a "Buy" or higher rating, and 7 have rated it "Hold." The median target price is $18. As of the previous trading day's close, the stock had gained 38.3% year to date.

路透社•2026/10/07 13:27